Hepatitis C virus diagnosis and testing

Canadian Journal of Public Health

Volumn 91, Issue SUPPL. 1, 2000, Pages

  Krajden, M ^a  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; IMMUNOGLOBULIN G; INTERFERON; NEW DRUG; NUCLEIC ACID; RIBAVIRIN; VIRUS ANTIGEN; VIRUS DNA; VIRUS ENZYME; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; DRUG EFFICACY; ENZYME IMMUNOASSAY; GENOTYPE; HEALTH CARE COST; HEPATITIS; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; LIVER; MASS SCREENING; MONITORING; NONHUMAN; NUCLEIC ACID ANALYSIS; PLASMA; PREVALENCE; QUANTITATIVE ASSAY; SEROCONVERSION; SERODIAGNOSIS; SERUM;

HEPATITIS C; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 0033759270     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection
2. New perspectives in the diagnosis of hepatitis C
3. Diagnosis tests for hepatitis C
4. Diagnostic tests for hepatitis C
5. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
6. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commerically available antibody tests to identify a significant number of patients with HCV infection
7. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury
8. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
9. Hepatitis C: Progress and problems
10. Transfusion medicine. First of two parts-blood transfusion
11. Hepatitis C: The clinical spectrum of disease
12. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the impelmentation of blood-donor screening
13. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
14. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
15. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
16. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C
17. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus
18. Serological and virological diagnostic tests for hepatitis C virus infection
19. Indeterminate results of the second-generation hepatitis C virus (HCV) recombinant immunoblot assay: Significance of high-level c22-3 reactivity and influence of HCV genotypes
20. Detection of hepatitis C virus by PCR in second-generation enzyme immunoassay-seropositive blood donors by using matched pairs of fresh frozen plasma and pilot tube sera
21. Confirmatory strategy of hepatitis C serology based on two screening assays in a diagnostic setting
22. Safety and efficacy of hepatitis C virus antibody screening of blood donors with two sequential screening assays
23. Comparison of two second-generation anti-hepatitis C virus ELISA on 21431 US blood donor samples
24. Diagnosis of hepatitis C
25. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
26. Quantitation of hepatitis G and C viruses in the liver: Evidence that hepatitis G virus is not hepatotropic
27. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays
28. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays
29. Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection
30. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
31. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection
32. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
33. Reliability of polymerase chain reaction for detection of hepatitis C virus
34. What technique should be used for routine detection and quantification of HBV DNA in clinical samples?
35. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
36. Establishment of the first international standard for nucleis acid amplification technology (NAT) assays for HCV RNA
37. Standardization: A progress report
38. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA
39. Multicenter evaluation of the Cobas Amplicor HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory
40. Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood
41. Second-generation line probe assay for hepatitis C virus genotyping
42. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test
43. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology
44. Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity?
45. Development of a simple and highly sensitive enzyme immuno-assay for hepatitis C virus core antigen
46. Interferon and ribavirin combination therapy: Indications and schedules
47. Both a 'magic bullet' and good aim are required to link public health interests and health care needs in HIV infection
48. Cost-effectiveness of screening patients for hepatitis C